Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3728 in stage III NSCLC after chemoradiotherapy and TQB2450
CTR20233168Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3728 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2023; status: terminated.
02
Drugs
TQB3728
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233168.